%PDF-1.3
%âãÏÓ
1 0 obj
<<
/OPM 1
/Type/ExtGState
>>
endobj
2 0 obj
<<
/SM 0.01
/Type/ExtGState
/FL 1
>>
endobj
3 0 obj
<<
/Length 10485
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 142.237 481.89 487.22 re
f
Q
q
BT
/F0 1 Tf
9 0 0 9 146.5879 621.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(SUMMARY)Tj
-2.36011 -2.22222 TD
(Acute dystonic reaction)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 57.6929 581.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.039 Tw
(By means of acute dystonic reaction associated with dehydro-)Tj
0 -1.11111 TD
0.01 Tc
0.115 Tw
(benzperydol administration in one case and metoclopramid)Tj
0 -1.11113 TD
0 Tc
0.098 Tw
(administration in other case, we discussed about the general)Tj
0 -1.11111 TD
0.018 Tw
(properties of the treatment protocol of acute dystonic reaction)Tj
T*
0.005 Tc
0.12 Tw
(and the side effects of dehydrobenzperydol and metoclopra-)Tj
0 -1.11112 TD
0 Tc
0 Tw
(mid.)Tj
ET
Q
q
BT
/F2 1 Tf
9 0 0 9 57.6929 511.7445 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Key words:)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 101.634 511.7445 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Acute dystonic reaction, dehydrobenzperydol, me-)Tj
-4.88234 -1.11112 TD
0 Tw
(toclopramid)Tj
ET
Q
q
BT
/F2 1 Tf
9 0 0 9 57.6929 481.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.041 Tw
(Anahtar kelimeler:)Tj
ET
Q
q
BT
/F1 1 Tf
9 0 0 9 131.4144 481.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.041 Tw
(Akut distonik reaksiyon, dehidrobenzperi-)Tj
-8.19128 -1.11112 TD
0 Tw
(dol, metoklopramid)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 57.6929 435.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.047 Tw
(Postoperatif bulant\335 ve kusma (PBK), y\335llard\335r anestezi-)Tj
0 -1.3 TD
0.055 Tc
0.07 Tw
(nin en \232nemli problemlerinden biridir. Kapur )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 270.3119 425.3844 Tm
0 Tr
0 0 0 1 k
0.055 Tc
0 Tw
((1))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 280.9634 422.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
(,)Tj
-22.32705 -1.3 TD
0.008 Tw
(1991\325de PBK i\215in \322Big Little Problem\323 tan\335m\335n\335 kullan)Tj
22.24439 0 TD
(-)Tj
-22.24439 -1.3 TD
0.05 Tw
(m\335\337t\335r. Watcha )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 120.0586 399.3844 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((2))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 132.3845 396.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.05 Tw
(ise 2000 y\335l\335nda Kapur\325un bu tan\335m\335-)Tj
-7.46916 -1.3 TD
0.021 Tc
0.104 Tw
(na de\333inirken, PBK i\215in kendi g\232r\237\337lerini \322Big, Big)Tj
T*
0 Tc
0 Tw
(Problem\323 tan\335mlamas\335 ile \232zetlemi\337tir.)Tj
0 -2.6 TD
0.067 Tw
(Postoperatif bulant\335 ve kusmay\335 \232nlemek i\215in, bir olgu)Tj
22.24441 0.00001 TD
(-)Tj
-22.24441 -1.30001 TD
0.05 Tw
(muzda dehidrobenzperidol (DHB), di\333er olgumuzda ise)Tj
0 -1.3 TD
0.011 Tw
(metoklopramid tedavisi sonras\335nda geli\337en akut distonik)Tj
T*
0.015 Tc
0.11 Tw
(reaksiyon nedeniyle, akut distonik reaksiyonun genel)Tj
T*
0 Tc
0.084 Tw
(\232zellikleri, tedavi yakla\337\335m\335 ve anestezi uygulamalar\335n-)Tj
T*
0.023 Tc
0.102 Tw
(da s\335k\215a kulland\335\333\335m\335z dehidrobenzperidol ile meto-)Tj
T*
0 Tc
0 Tw
(klopramidin yan etkileri tart\335\337\335lm\335\337t\335r.)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 240.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(OLGULAR)Tj
ET
Q
q
BT
/F0 1 Tf
9 0 0 9 57.6929 217.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.063 Tw
(Olgu 1:)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 89.8239 217.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.063 Tw
(37 ya\337\335nda, ASA I risk s\335n\335f\335nda, preoperatif d\232nem)Tj
21.18287 0 TD
(-)Tj
-24.75298 -1.11112 TD
0.016 Tc
0.109 Tw
(de devaml\335 kulland\335\333\335 farmakolojik medikasyonu olmayan,)Tj
0 -1.11111 TD
0.009 Tc
0.116 Tw
(bayan hasta. Elektif laparoskopik t\237p ligasyonu operasyonu)Tj
T*
0 Tc
0.108 Tw
(i\215in tiopental sodyum, s\237ksinil kolin ind\237ksiyonu sonras\335 so-)Tj
T*
0.064 Tw
(runsuz ent\237be edilen ve anestezi idamesinde N)Tj
ET
Q
q
BT
/F3 1 Tf
7 0 0 7 229.5763 175.4344 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 233.0763 177.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0.064 Tw
(O, O)Tj
ET
Q
q
BT
/F3 1 Tf
7 0 0 7 251.147 175.4344 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 257.4731 177.7444 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
<7461DFDD79DD63DD>Tj
-22.1978 -1.11111 TD
0.022 Tw
(gaz kar\335\337\335m\335 i\215erisinde isofluran kullan\335lan hastan\335n 25 dk. s\237)Tj
24.753 0 TD
(-)Tj
-24.753 -1.11112 TD
0.007 Tc
0.118 Tw
(ren operasyon s\335ras\335nda anestezi y\232netimi sorunsuz seyretti.)Tj
0 -1.11111 TD
0 Tc
0.043 Tw
(Ekst\237basyonu takiben postoperatif d\232nemde bulant\335 ve kusma)Tj
28.23535 52.62956 TD
0.03 Tw
(geli\337mesi \237zerine 1.25 mg dehidrobenzperidol (DHB) intrave-)Tj
0 -1.11111 TD
0.057 Tw
(n\232z olarak yap\335ld\335. \334lac\335n yap\335lmas\335n\335 takiben 15 dakika i\215eri-)Tj
T*
0.03 Tc
0.095 Tw
(sinde boyunda kas\335lma, g\232zlerde sa\333a deviasyon, v\237cutta)Tj
T*
0.032 Tc
0.093 Tw
(opistotonus duru\337u meydana geldi. \334la\215 al\335nd\335ktan 30 dk.)Tj
T*
0.005 Tc
0.12 Tw
(sonra t\237m v\237cutta se\333irme tarz\335 yayg\335n kas\335lmalar, boyunda)Tj
T*
0.015 Tc
0.11 Tw
(kas\335lma, disfazi, disfaji, hiperhidrozis g\232zlendi. Laboratuar)Tj
T*
0.008 Tc
0.117 Tw
[(de\333erlendirmesinde;)-375(AST)-375(48, ALT)-375(84, LDH)-375(335, CPK)-375(246)]TJ
T*
0 Tc
0.037 Tw
(olarak bulundu. Hastan\335n tablosu DHB\325nin neden oldu\333u akut)Tj
T*
0.005 Tc
0.119 Tw
(distonik reaksiyon olarak de\333erlendirildi. \334)Tj
17.79785 0 TD
[(n)-1(tramusk\237ler ola-)]TJ
-17.79785 -1.11112 TD
0 Tc
0.008 Tw
(rak biperidin uygulanan hastan\335n bulgular\335 45 dk. sonra gerile-)Tj
0 -1.11111 TD
0.101 Tw
(di ve 2 saat sonra tamamen normale d\232nd\237. Hasta ertesi g\237n)Tj
T*
0 Tw
(sorunsuz olarak taburcu edildi.)Tj
ET
Q
q
BT
/F0 1 Tf
9 0 0 9 311.811 491.4104 Tm
0 Tr
0 0 0 1 k
-0.005 Tc
0.098 Tw
(Olgu 2:)Tj
ET
Q
q
BT
/F3 1 Tf
9 0 0 9 344.209 491.4104 Tm
0 Tr
0 0 0 1 k
-0.005 Tc
0.098 Tw
(16 ya\337\335nda ASA I, preoperatif d\232nmede herhangi bir)Tj
-3.59978 -1.11111 TD
0.039 Tw
(ila\215 kullan\335m \232yk\237s\237 bulunmayan erkek hasta. Hidatik kist ne-)Tj
T*
0.109 Tw
(deniyle opere edilen hastada genel cerrahi servisindeki posto-)Tj
T*
0 Tc
0.12 Tw
(peratif takibinin ikinci g\237n\237nde v\237cutta se\333irme tarz\335 yayg\335n)Tj
T*
-0.005 Tc
0.085 Tw
(kas\335lmalar, boyunda kas\335lma, g\232zlerde deviasyon, disfazi, dis)Tj
24.75297 0 TD
0 Tc
(-)Tj
-24.75297 -1.11112 TD
-0.005 Tc
0.02 Tw
(faji, parkinsonizm bulgular\335, hiperhidrozis, 37.8\241C\325ye kadar \215\335-)Tj
0 -1.11111 TD
0.006 Tc
0.113 Tw
(kan v\237cut \335s\335s\335 g\232zlendi. G\232nderilen laboratuar de\333erlerinde)Tj
T*
-0.005 Tc
0 Tw
(AST)Tj
2.16915 0 TD
0.05 Tw
[(52, ALT)-296(61, CPK)-295(322 olarak bulundu. Tedavisi sefepim,)]TJ
-2.16915 -1.11112 TD
-0.001 Tc
0.121 Tw
(metoklopramid ve omeprazol olarak d\237zenlenmi\337 olan hasta-)Tj
0 -1.11111 TD
-0.005 Tc
0.024 Tw
(n\335n tablosu, metoklopramidin neden oldu\333u akut distonik reak)Tj
24.75299 0 TD
0 Tc
(-)Tj
-24.75299 -1.11111 TD
-0.005 Tc
0.046 Tw
(siyon olarak de\333erlendirildi. Metoklopramid tedavisi durduru)Tj
24.48015 0 TD
0 Tc
(l)Tj
0.27283 0 TD
(-)Tj
-24.75299 -1.11112 TD
-0.002 Tc
0.122 Tw
(du ve intramusk\237ler olarak biperidin tedaviye eklendi. 1 saat)Tj
0 -1.11111 TD
-0.005 Tc
0.053 Tw
(sonra bulgular\335 gerileyen hasta, 3 saat sonra tamamen normale)Tj
T*
0 Tw
(d\232nd\237 ve postoperatif takibi sorunsuz seyretti.)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 311.811 335.4104 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(TARTI\336MA)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 311.811 309.4104 Tm
0 Tr
0 0 0 1 k
0 Tc
0.07 Tw
(Bulant\335, \232\333\237rme ve kusma postoperatif d\232nemde genel,)Tj
0 -1.3 TD
0.005 Tc
0.12 Tw
(rejyonel ya da lokal anestezi sonras\335 geli\337ebilecek ya)Tj
22.24452 0.00001 TD
0 Tc
(-)Tj
-22.24452 -1.30001 TD
0.002 Tc
0.123 Tw
(k\335nmalar aras\335nda en s\335k kar\337\335la\337\335lanlardand\335r. Bulant\335,)Tj
0 -1.3 TD
0.009 Tc
0.116 Tw
(kusmaya y\232nelimin fark\335na var\335lmas\335 ile b\237t\237nle\337mi\337;)Tj
T*
0 Tc
0.031 Tw
(\232znel, ho\337 olmayan bir his olarak tan\335mlan\335r. Kusma ise)Tj
T*
0.015 Tw
(gastro\232zofageal sfinkterin gev\337emesi, diyafragman\335n in-)Tj
T*
0.101 Tw
(mesi ve kar\335n duvar\335 kaslar\335n\335n g\237\215l\237 bir \337ekilde kas\335l-)Tj
T*
0.048 Tw
(mas\335 ile birlikte mide i\215eri\333inin a\333\335zdan zorlu at\335l\335m\335d\335r)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 311.811 208.0504 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((2))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 321.1352 205.4104 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.60485 0 Td
0 Tc
0.105 Tw
(Yap\335lan \215al\335\337malarda)Tj
8.57285 0.00001 TD
[(,)-355<50424B2073DD6B6CDDDBDD>-355(% 8-92 aras\335nda)]TJ
-10.11011 -1.30001 TD
0 Tw
(de\333i\337mektedir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 371.9929 195.0505 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((3))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 381.3171 192.4104 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.60345 0 Td
0 Tc
0.104 Tw
(Jinekolojik giri\337imlerde ise bu s\335kl\335k)Tj
-7.55406 -1.3 TD
-0.0001 Tc
(%)Tj
1.08282 0 Td
0 Tc
0 Tw
(58-77 gibi y\237ksek oranlara ula\337maktad\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 486.7451 182.0504 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((4))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 496.0693 179.4104 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-18.42583 -2.6 TD
0.076 Tw
(H\335zla geli\337en anestezi biliminde PBK \237zerine etkin, fe-)Tj
ET
0 0 0 0 k
56.693 655.457 481.89 73.047 re
f
Q
q
BT
/F0 1 Tf
20 0 0 20 57.6929 712.5873 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Akut distonik reaksiyon)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 660.5873 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Volkan HANCI (*))Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 642.618 m
538.583 642.618 l
S
0 0 0 0 k
56.693 119.055 481.89 11.512 re
f
Q
q
BT
/F3 1 Tf
8 0 0 8 57.6929 123.3038 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Denizli \205zel Sa\333l\335k Hastanesi, Uz. Dr.*)Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 137.89 m
538.583 137.89 l
S
57.78 755.355 m
539.669 755.355 l
S
0 0 0 0 k
56.693 752.851 481.89 13 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 757.021 Tm
0 Tr
0 0 0 1 k
0.1 Tc
0 Tw
(OLGU SUNUMU)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 2.12557 10 377.1928 757.021 Tm
0 Tr
0 0 0 1 k
0.1 Tc
0 Tw
(Anesteziyoloji ve Reanimasyon)Tj
ET
0 J 0 j 10 M []0 d 1 w
0 0 0 1 K
56.693 748.351 m
538.583 748.351 l
S
56.693 771.024 m
538.583 771.024 l
S
56.693 461.725 m
283.465 461.725 l
S
0 0 0 0 k
56.693 789.197 127.626 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 57.6929 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(G\232ztepe T\335p Dergisi 20(1):53-56, 2006)Tj
ET
0 0 0 0 k
526.249 92.168 12.334 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 527.2488 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(53)Tj
ET
0 0 0 0 k
470.551 788.1971 68.027 11.1729 re
f
Q
q
BT
/F0 1 Tf
9 0 0 9 471.551 791.6577 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(ISSN 1300-526X)Tj
ET
Q
endstream
endobj
4 0 obj
<<
/Length 12658
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 119.055 481.89 637.796 re
f
Q
q
BT
/F3 1 Tf
10 0 0 10 57.6929 748.021 Tm
0 Tr
0 0 0 1 k
0.0007 Tc
(n)Tj
0.5007 0.00001 TD
0.001 Tc
0.124 Tw
(otiyazinler, butirofenonlar, antihistaminikler, antikoli-)Tj
-0.5007 -1.30001 TD
0 Tc
0.031 Tw
(nerjikler, benzamidler gibi bir \215ok ajan kullan\335lm\335\337t\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 274.8026 737.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(\(2,)Tj
-27.13871 -1.625 TD
(5\))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 64.355 722.0211 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.54491 0.00001 TD
0 Tc
0.045 Tw
(Dehidrobenzperidol (DHB), butirofenon t\237revi n\232ro-)Tj
-1.21112 -1.30001 TD
0.107 Tw
(leptik bir ila\215t\335r. Molek\237ler yap\335s\335 haloperidole benzer.)Tj
0 -1.3 TD
0.072 Tw
(Dopamin resept\232r antagonistidir. Santral sinir sistemin-)Tj
T*
0.03 Tc
0.095 Tw
(de n\237kleus kaudatus ve kemoresept\232r trigger zonda)Tj
T*
0 Tc
0.001 Tw
((CTZ); serotonin, norepinefrin, ve dopamin resept\232rleri-)Tj
T*
0.013 Tw
(nin a\337\335m\335n\335 etkiler )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 133.3463 659.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 148.6705 657.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.51297 0 Td
0 Tc
0.013 Tw
(Droperidol d\237\337\237k maliyet-etkin-)Tj
-9.61073 -1.3 TD
0.119 Tw
(lik oran\335 ile dikkat \215eken bir antiemetiktir. \202al\335\337malar,)Tj
T*
0.014 Tc
0.111 Tw
(yeti\337kinlerde droperidol\237n ondansetron kadar g\237venli)Tj
T*
0 Tc
0.043 Tw
(ve etkili oldu\333u g\232stermi\337tir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 174.9429 620.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((8,9))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 190.2671 618.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.54277 0 Td
0 Tc
0.043 Tw
(Geni\337, prospektif pla-)Tj
-13.80019 -1.3 TD
0.04 Tw
[(sebo kontroll\237 bir \215al\335\337mada,)-290(0.625 mg droperidol, 1.25)]TJ
T*
0.024 Tc
0.101 Tw
(mg droperidol veya 4 mg ondansetron 2000 hastada)Tj
T*
0.008 Tc
0.117 Tw
(PBK tedavisi amac\335yla kullan\335lm\335\337 ve ila\215lar aras\335nda)Tj
T*
0.021 Tc
0.104 Tw
[<50424B2073DD6B6CDDDBDD>-375(a\215\335s\335ndan fark bulunamam\335\337t\335r )]TJ
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 245.4248 568.6611 Tm
0 Tr
0 0 0 1 k
0.021 Tc
0 Tw
((9))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 255.2622 566.0211 Tm
0 Tr
0 0 0 1 k
0.0213 Tc
(.)Tj
0.64622 0 Td
0.021 Tc
0 Tw
(Daha)Tj
-20.40315 -1.3 TD
0.001 Tc
0.124 Tw
[(\232nemlisi,)-375(ayn\335 \215al\335\337mada ila\215lar\335n yan etkileri aras\335nda)]TJ
T*
0 Tc
0.019 Tw
(anlaml\335 farkl\335l\335\333a rastlanmam\335\337t\335r. Bu bulgular Henzi ve)Tj
0 -1.30001 TD
0 Tw
(ark. )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 75.6639 529.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((10))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 91.693 527.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
0.02 Tw
(taraf\335ndan 24 farkl\335 droperidol kullanma rejimi-)Tj
-3.40001 -1.3 TD
0.02 Tc
0.105 Tw
[(ni i\215eren 76 \215al\335\337man\335n sonu\215lar\335n\335n analiz et)1(t)1(i\333i bir)]TJ
0 -1.30001 TD
0 Tc
0 Tw
(meta-analiz ile de do\333rulanm\335\337t\335r. )Tj
0 -2.6 TD
0.007 Tc
0.118 Tw
(DHB\325ye ba\333l\335 g\232zlenen yan etkiler; l\232kopeni, nadiren)Tj
0 -1.3 TD
0 Tc
0.051 Tw
(aplastik anemi gibi hematolojik bozukluklar; a\333\335z kuru-)Tj
T*
0.088 Tw
(lu\333u, \237riner retansiyon, ta\337ikardi gibi kolinerjik etkiler;)Tj
T*
0.015 Tw
(periferik alfa adrenerjik resept\232r blokaj\335na ba\333l\335 \232zellik)Tj
22.2444 0 TD
(-)Tj
-22.2444 -1.3 TD
0.021 Tc
0.104 Tw
(le hipovolemik hastalarda g\232zlenebilen hipotansiyon)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 57.6929 412.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((11))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 71.0171 410.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(,)Tj
0.5235 0 Td
0 Tc
0.024 Tw
(hepatosell\237ler zedelenme, kolestatik sar\335l\335k gibi he-)Tj
-1.85592 -1.3 TD
0.099 Tw
(patik bozukluklar )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 132.4228 399.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 147.7471 397.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(,)Tj
0.59852 0 Td
0 Tc
0.099 Tw
(QT uzamas\335, torsades des poin-)Tj
-9.60394 -1.3 TD
0.011 Tc
0.114 Tw
(tes gibi ileti bozukluklar\335 )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 168.1806 386.6611 Tm
0 Tr
0 0 0 1 k
0.011 Tc
0 Tw
((11-13))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 192.8048 384.0211 Tm
0 Tr
0 0 0 1 k
0.0113 Tc
(,)Tj
0.63624 0 Td
0.011 Tc
0.114 Tw
(anjio\232dem gibi ana-)Tj
-14.14743 -1.3 TD
0 Tc
0.042 Tw
(filaktik reaksiyonlar )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 141.8341 373.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((14))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 155.1584 371.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(,)Tj
0.54214 0 Td
0 Tc
0.042 Tw
(dezoryantasyon, hal\237sinasyon,)Tj
-10.28869 -1.3 TD
0.124 Tw
(disfori, konv\237lziyonlara e\333ilimde art\335\337, ekstrapiramidal)Tj
T*
0.011 Tc
0.114 Tw
[(bozukluklar ve n\232roleptik habis)-375(sendrom )]TJ
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 234.286 347.6611 Tm
0 Tr
0 0 0 1 k
0.011 Tc
0 Tw
((6,11))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 257.9092 345.0211 Tm
0 Tr
0 0 0 1 k
0.011 Tc
0 Tw
(olarak)Tj
-20.02163 -1.3 TD
0 Tc
(\232zetlenebilir.)Tj
0 -2.6 TD
0.056 Tw
[(Son y\335llarda,)-306(droperidol\237n kardiyak yan etkileri s\335kl\335kla)]TJ
0 -1.3 TD
0.106 Tw
(tart\335\337ma konusu olmaktad\335r. Literat\237rde y\237ksek dozlar)Tj
22.2444 0 TD
(-)Tj
-22.2444 -1.30001 TD
0 Tw
(da droperidol ile artm\335\337 kardiyak morbidite ve mortalite;)Tj
0 -1.3 TD
0.059 Tw
(d\237\337\237k dozda droperidol ile QT uzamas\335 ve torsades des)Tj
T*
0.012 Tc
0.113 Tw
(pointes sendromu tan\335mlanm\335\337t\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 198.9552 256.6611 Tm
0 Tr
0 0 0 1 k
0.011 Tc
0 Tw
((13))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 212.6517 254.021 Tm
0 Tr
0 0 0 1 k
0.012 Tc
0.113 Tw
[(.)-375(Amerikan G)1
1(d)1(a)]TJ
-15.49588 -1.3 TD
0 Tc
0.12 Tw
(ve \334la\215 Dairesi (FDA) verilerine g\232re Kas\335m 1997\325den)Tj
T*
(Ocak 2002\325ye kadar olan s\237rede droperidole ba\333l\335 yan)Tj
T*
0.025 Tw
(etki g\232zlenen 273 olgu ve droperidol ile ili\337kili 89 \232l\237m)Tj
T*
0.003 Tc
0.122 Tw
[(bildirilmi\337tir. Fakat,)-375(bunlardan sadece 2 tanesi 2.5 mg)]TJ
T*
0.002 Tc
0.123 Tw
(veya daha az dozda droperidol verilmesi ile ili\337kilidir.)Tj
T*
0.007 Tc
0.118 Tw
(\205l\237mlerin b\237y\237k k\335sm\335nda kullan\335lan droperidol dozu)Tj
T*
0.008 Tc
0.117 Tw
(25-250 mg aras\335nda de\333i\337mektedir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 205.9564 165.6612 Tm
0 Tr
0 0 0 1 k
0.007 Tc
0 Tw
((12))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 219.5235 163.021 Tm
0 Tr
0 0 0 1 k
0.0075 Tc
(.)Tj
0.63243 0 Td
0.008 Tc
0.117 Tw
(Ayn\335 raporda,)Tj
-16.81549 -1.3 TD
0 Tc
0 Tw
(torsades veya uzam\335\337 QT intervaline, ciddi yan etki g\232z)Tj
22.24442 0.00001 TD
(-)Tj
-22.24442 -1.30001 TD
0.015 Tc
0.11 Tw
(lenen 127 hastan\335n 17\325sinde rastland\335\333\335 bildirilmi\337tir.)Tj
0 -1.3 TD
0.004 Tc
0.121 Tw
(Kardiyak morbidite ise bu hastalar\335n 74\325\237nde mevcut-)Tj
25.41181 62.40001 TD
-0.0001 Tc
(t)Tj
0.27793 0.00001 TD
0 Tc
0.031 Tw
(ur. Bu hastalardan 2.5 mg veya daha az droperidol kul-)Tj
-0.27793 -1.30001 TD
0.093 Tw
(lan\335lan toplam 5 hastadan 2\325sinde ventrik\237ler ta\337ikardi,)Tj
0 -1.3 TD
(3)Tj
0.5 0.00001 TD
0.037 Tw
(\325\237nde ise torsades g\232zlendi\333i, tablonun hastalardan sa-)Tj
-0.5 -1.30001 TD
0 Tw
(dece birinde fatal sonu\215land\335\333\335 belirtilmi\337tir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 489.7993 711.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((12))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 503.1235 709.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-19.13125 -2.6 TD
0.012 Tw
(\334la\215lar\335n ind\237kledi\333i torsades de pointes\325in elektrofizyo-)Tj
0 -1.3 TD
0.037 Tw
(lojik mekanizmas\335 a\215\335k de\333ildir. Bir serotonin resept\232r\237)Tj
T*
0.014 Tc
0.111 Tw
(olan 5-hidroksitriptamin subtip 3\325\237n (5-HT3) selektif)Tj
T*
0 Tc
0.017 Tw
(antagonistlerini de i\215eren geni\337 bir yelpazedeki ila\215 gru-)Tj
T*
0.01 Tc
0.115 Tw
(bu da QT intervalini uzat\335p, teorik olarak torsades de)Tj
T*
0 Tc
0 Tw
(pointes nedeni olabilir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 403.7391 620.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((15))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 417.0633 618.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.50011 0 Td
0 Tc
0 Tw
(Dolasetronun aktif metaboli-)Tj
-11.02534 -1.3 TD
0.024 Tc
0.101 Tw
(ti olan hidrodolasetronun neden oldu\333u QT uzamas\335)Tj
T*
0.001 Tc
0.124 Tw
(sa\333l\335kl\335 g\232n\237ll\237ler \237zerindeki kontroll\237 klinik \215al\335\337ma-)Tj
T*
0 Tc
0 Tw
(larda g\232zlenmi\337tir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 386.7793 581.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((16))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 400.1035 579.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-8.82925 -2.6 TD
0.009 Tc
0.116 Tw
[(Metoklopramid,)-375(benzamid t\237revi bir dopamin antago-)]TJ
0 -1.3 TD
0 Tc
0.004 Tw
(nistidir. Farmakolojik etki profili ana hatlar\335 ile n\232rolep)Tj
22.24441 0 TD
(-)Tj
-22.24441 -1.30001 TD
0.12 Tw
(tik ila\215lara benzemekte ve onlar gibi kemoresept\232r tri-)Tj
0 -1.3 TD
0.025 Tc
0.099 Tw
(ger zonu (CTZ) inhibe ederek g\237\215l\237 antiemetik etki)Tj
0 -1.30001 TD
0.005 Tc
0 Tw
(yapmaktad\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 366.1089 503.6611 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0 Tw
((17))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 379.5989 501.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
0.63018 0.00001 TD
0.005 Tc
0.12 Tw
(Henzi ve ark. )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 446.2996 503.6611 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0 Tw
((18))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 463.5396 501.0211 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0.12 Tw
(1999 y\335l\335nda, me)Tj
7.07155 0.00001 TD
0 Tc
(-)Tj
-22.24441 -1.30001 TD
0.019 Tc
0.106 Tw
(toklopramidin 18 de\333i\337ik rejiminin kullan\335ld\335\333\335 3260)Tj
0 -1.3 TD
0 Tc
0.051 Tw
(hastadan ve toplam 66 \215al\335\337man\335n sonu\215lar\335ndan olu\337an)Tj
T*
0.045 Tw
(meta analizlerinde; metoklopramidin yakla\337\335k 40 y\335ldan)Tj
T*
0.032 Tw
(beri PBK\325de etkin olarak kullan\335ld\335\333\335n\335 ve ucuz oldu\333u-)Tj
T*
0.01 Tc
0.115 Tw
(nu, di\333er antiemetiklerin metoklopramide belirgin \237s)Tj
22.24426 0 TD
0 Tc
(-)Tj
-22.24426 -1.3 TD
0.045 Tw
(t\237nl\237klerinin olmamas\335na kar\337\335n pahal\335 olduklar\335n\335; me)Tj
22.24439 0 TD
(-)Tj
-22.24439 -1.3 TD
0.011 Tc
0.114 Tw
(toklopramidin yan etkilerinden ekstrapiramidal semp-)Tj
T*
0 Tc
0.04 Tw
(tomlar\335n \215ocuklarda hi\215 rapor edilmedi\333ini, eri\337kinlerde)Tj
T*
0 Tw
(ise PBK\325de kullan\335lan d\237\337\237k dozlarda bunun nadir oldu-)Tj
T*
0.028 Tw
(\333unu; sedasyon, halsizlik, ba\337 a\333r\335s\335, ba\337 d\232nmesi d\335\337\335n-)Tj
T*
0.084 Tw
(da ta\337ikardi, g\237\215s\237zl\237k gibi yan etkilerin de rapor edil-)Tj
T*
0.001 Tc
0.124 Tw
[(di\333ini,)-375(ama bunlar\335n plasebo ile istatistiksel olarak an-)]TJ
T*
0 Tc
0 Tw
(laml\335 farkl\335l\335k g\232stermedi\333ini bildirmi\337lerdir. )Tj
0 -2.6 TD
0.002 Tc
0.123 Tw
(Metoklopramidin en s\335k g\232zlenen yan etkileri uyu\337uk-)Tj
0 -1.3 TD
0 Tc
0.024 Tw
(luk, a\333\335z kurulu\333u, konstipasyon, )Tj
13.67589 0 TD
0 Tw
(ishal)Tj
1.88843 0 TD
-0.0001 Tc
(,)Tj
0.52345 0 Td
0 Tc
0.024 Tw
(halsizlik ve cilt)Tj
6.15664 0 TD
(-)Tj
-22.2444 -1.30002 TD
0.001 Tc
0.124 Tw
(te alerjik d\232k\237nt\237lerdir. Bazen ajitasyon, methemoglo-)Tj
0 -1.3 TD
0.006 Tc
0.118 Tw
(binemi, dilde ve orbitada \232dem yapabilir. Uzun s\237reli)Tj
T*
0 Tc
0.028 Tw
(veya y\237ksek dozda k\335sa s\237re kullan\335ld\335\333\335nda, distonilere)Tj
T*
0.014 Tc
0.111 Tw
(ve parkinsonizm benzeri tremor, rijidite ve akineziye)Tj
T*
0.009 Tc
0.116 Tw
(neden olabilir. Uzun s\237re kullan\335m\335 tardif diskineziye)Tj
T*
0 Tc
0.016 Tw
(neden olabilir. Akatisi \337eklinde diskinezinin h\335zl\335 )Tj
20.00682 0.00001 TD
0 Tw
[(iv.)-266(en-)]TJ
-20.00682 -1.30001 TD
0.01 Tc
0.115 Tw
(jeksiyonu sonras\335 akut olarak g\232zlenebilece\333i belirtil-)Tj
0 -1.3 TD
0 Tc
0.095 Tw
(mi\337tir. Epileptik hastalar\335nda n\232bet aktivitesini ba\337lata)Tj
22.2444 0.00001 TD
(-)Tj
-22.2444 -1.30001 TD
0.004 Tc
0.12 Tw
(bilece\333i, feokromositomal\335 hastalarda hipertansif krize)Tj
0 -1.3 TD
0 Tc
0.088 Tw
(neden olabilece\333i i\215in bu hasta gruplar\335nda kullan\335lma-)Tj
T*
0.024 Tw
(mal\335d\335r. Sedatif ila\215lar\335n, n\232roleptik ila\215lar\335n ve trisiklik)Tj
T*
0.006 Tc
0.119 Tw
(antidepresanlar\335n etkinlik ve toksisitesini art\335rd\335\333\335 i\215in)Tj
T*
0.001 Tc
0.124 Tw
(bu ila\215larla birlikte kullan\335lmamal\335d\335r. MAO inhibit\232r-)Tj
ET
0 0 0 0 k
410.956 789.197 127.627 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 411.9562 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(G\232ztepe T\335p Dergisi 20(1):53-56, 2006)Tj
ET
0 0 0 0 k
56.693 92.168 12.334 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(54)Tj
ET
Q
endstream
endobj
5 0 obj
<<
/Length 11670
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 119.055 481.89 637.796 re
f
Q
q
BT
/F3 1 Tf
10 0 0 10 57.6929 748.021 Tm
0 Tr
0 0 0 1 k
0.0018 Tc
(l)Tj
0.27977 0.00001 TD
0.002 Tc
0.123 Tw
(erinin de metoklopramidin toksisitesini art\335rd\335\333\335 bilin-)Tj
-0.27977 -1.30001 TD
0 Tc
0 Tw
(mektedir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 95.7325 737.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((17))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 109.0567 735.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-5.13638 -2.6 TD
0.011 Tc
0.113 Tw
(Temel farmakolojik etkilerin uzant\335s\335 ve \337iddetlenmi\337)Tj
0 -1.3 TD
0 Tc
0.005 Tw
[(\337ekli olarak kabul edilen ekstrapiramidal yan etkiler,)-255(ba-)]TJ
0.0027 Tc
(zal)'
1.54901 0 Td
0.003 Tc
0.122 Tw
(gangliyonlar\335n dopaminerjik resept\232rlerinin blokaj\335)Tj
-1.54901 -1.3 TD
0.001 Tc
0.124 Tw
(sonucunda olu\337ur. Antidopaminerjik etkinli\333i g\237\215l\237 ve)Tj
T*
0 Tc
0.033 Tw
(antikolinerjik etkinli\333i d\237\337\237k ila\215larla daha belirgin ola-)Tj
T*
0.063 Tw
(rak meydana gelir. D\232rt tip ekstrapiramidal yan etki ta-)Tj
T*
0.023 Tw
(n\335mlanmaktad\335r; akut distonik reaksiyonlar, akatisi, par-)Tj
T*
0 Tw
(kinsonizm ve tardif diskinezi )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 176.5455 620.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7,14))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 201.8697 618.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-14.41768 -2.6 TD
0.003 Tc
0.122 Tw
(Akut distonik reaksiyon ila\215lar\335n verilmesinden birka\215)Tj
0 -1.3 TD
0.008 Tc
0.117 Tw
(saat ile birka\215 g\237n veya hafta sonra olu\337abilmektedir.)Tj
T*
0.011 Tc
0.114 Tw
(\202ocuklarda ve gen\215 eri\337kinlerde ya\337l\335lara, bayanlarda)Tj
T*
0 Tc
0.024 Tw
(erkeklere oranla daha s\335k g\232zlenmektedir. G\232z, dil, y\237z,)Tj
T*
0.031 Tw
(a\333\335z, boyun ve s\335rt kaslar\335nda devaml\335 kas spazm\335, buna)Tj
0 -1.30001 TD
0.017 Tw
(ba\333l\335 olarak displastik tortikolis, boyunda hiperekstansi-)Tj
0 -1.3 TD
0.074 Tw
(yon (opistotonus), perioral spazm, mandib\237ler tik, ok\237-)Tj
0 -1.30001 TD
0.08 Tw
(lerjik kriz, disfaji, disfazi ve nadiren laringospazm olu)Tj
22.24441 0.00001 TD
(-)Tj
-22.24441 -1.30001 TD
0 Tw
(\337ur )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 73.5555 490.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7,14))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 98.8798 488.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
0.97916 0 Td
0.115 Tw
[(Laringeal disfonksiyon,)-365(ila\215lar\335n neden ol-)]TJ
-5.09785 -1.3 TD
0.008 Tw
(du\333u anjion\232rotik \232deme e\337lik edebilece\333i gibi akut dis-)Tj
T*
0.024 Tw
(toni belirtilerinden biri olarak da ortaya \215\335kabilmekte ve)Tj
T*
0 Tw
(genellikle dispne ile kendini belli etmektedir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 238.7476 451.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((19))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 252.0718 449.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-19.43789 -2.6 TD
0.093 Tw
(Spastik belirtilerle birlikte hiperhidroz, solukluk ve be)Tj
22.2444 0 TD
(-)Tj
-22.2444 -1.3 TD
0.062 Tw
(lirgin anksiyete g\232zlenir. Hastalarda anksiyete nedeniy-)Tj
T*
0.007 Tc
0.118 Tw
(le ta\337ikardi g\232zlenebilir. Geri d\232n\237\337\237ml\237 reaksiyonlar)Tj
T*
0.008 Tc
0.117 Tw
(olmakla birlikte, difenhidramin, benztropin, biperidin,)Tj
T*
(triheksifenidil gibi santral antikolinerjik antiparkinson)Tj
T*
0 Tc
0.047 Tw
(ila\215lar ve diazepamla bu belirtiler d\237zeltilebilir. Bunun-)Tj
-0.0001 Tc
(la)'
1.04744 0 Td
0 Tc
0.076 Tw
[(beraber,)-326(difenhidramin ve diazepam da akut distonik)]TJ
-1.04744 -1.3 TD
0 Tw
(reaksiyona neden olabilmektedir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 190.6934 334.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7,19-21))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 226.6797 332.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-16.89868 -2.6 TD
0.004 Tc
0.121 Tw
(Akut distonik reaksiyon n\232roleptikler, ranitidin )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 257.4045 308.6612 Tm
0 Tr
0 0 0 1 k
0.004 Tc
0 Tw
((22,23))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 280.9633 306.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(,)Tj
-22.32704 -1.3 TD
0.017 Tw
(eritromisin, kokain, fenobarbital, sisaprid, buspiron, flu)Tj
22.24441 0 TD
(-)Tj
-22.24441 -1.30001 TD
0.111 Tw
(voksamin, metoklopramid )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 167.3966 282.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((24,25))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 194.3324 280.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.111 Tw
(ve verapamil )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 250.9721 282.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((26))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 267.9079 280.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(gibi)Tj
-21.0215 -1.3 TD
0.001 Tw
(ila\215larla ortaya \215\335kabilmektedir. Granisetron uygulamas\335)Tj
T*
0.007 Tc
0.118 Tw
(ile kesinlikle ili\337kili olan herhangi bir ekstrapiramidal)Tj
T*
0.009 Tc
0.116 Tw
(etki ise rapor edilmemi\337tir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 172.605 243.6611 Tm
0 Tr
0 0 0 1 k
0.009 Tc
0 Tw
((27))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 186.2193 241.021 Tm
0 Tr
0 0 0 1 k
0.009 Tc
0.116 Tw
[(.)-375(Droperidol uygulanan)]TJ
-12.85264 -1.3 TD
0.026 Tc
0.099 Tw
(hastalar\335n \215ok d\237\337\237k bir y\237zdesinde ekstrapiramidal)Tj
T*
0.001 Tc
0.124 Tw
(bulgular olu\337ur. Literat\237rde droperidol\237n 0.65 mg gibi)Tj
T*
0.008 Tc
0.117 Tw
(d\237\337\237k dozlar\335nda bile ekstrapiramidal reaksiyonlar ta-)Tj
T*
0 Tc
0 Tw
(n\335mlanm\335\337t\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 112.3142 191.6612 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 121.6384 189.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
0.60167 0 Td
0.102 Tw
(\334lk olgumuzda da 1.25 mg gibi d\237\337\237k)Tj
-6.99622 -1.3 TD
0.088 Tw
(bir droperidol dozu ile ekstrapiramidal yan etkiler g\232z)Tj
22.24439 0.00001 TD
(-)Tj
-22.24439 -1.30001 TD
0 Tw
(lenmi\337tir.)Tj
0 -2.6 TD
0.089 Tw
(\334ntraven\232z ve intramusk\237ler uygulama d\335\337\335nda epidural)Tj
0 -1.3 TD
0.008 Tc
0.117 Tw
(droperidol uygulanmas\335 sonras\335nda da ekstrapiramidal)Tj
25.41181 62.40001 TD
-0.0001 Tc
(r)Tj
0.3329 0.00001 TD
0 Tc
0.028 Tw
[(eaksiyonlar tan\335mlanm\335\337t\335r. Yotsui ve ark.,)-278(postoperatif)]TJ
-0.33289 -1.30001 TD
0.004 Tc
0.121 Tw
(bulant\335 ve kusmay\335 \232nleme amac\335yla epidural droperi-)Tj
0 -1.3 TD
0.0119 Tc
(d)Tj
0.51188 0.00001 TD
0.012 Tc
0.113 Tw
(ol kulland\335klar\335 iki hastada ekstrapiramidal belirtiler)Tj
-0.51188 -1.30001 TD
0.003 Tc
0.122 Tw
[(rapor etmi\337ler,)-375(ancak bu reaksiyonlar\335 hastalara posto-)]TJ
0 -1.3 TD
0.027 Tc
0.098 Tw
(peratif antiemetik ama\215l\335, intraven\232z yoldan verilen)Tj
T*
0.016 Tc
0.109 Tw
(droperidol ve metoklopramid ile ili\337kili olabilece\333ini)Tj
T*
0 Tc
0 Tw
(d\237\337\237nm\237\337lerdir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 376.7984 672.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((28))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 390.1226 670.021 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(.)Tj
0.52786 0 Td
0 Tc
0.028 Tw
[(Shimada ve ark.)-278(ise,)-278(kronik a\333r\335 te-)]TJ
-8.35902 -1.3 TD
0.003 Tc
0.122 Tw
(davisi amac\335yla 2.5 mg g\237n)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 427.8312 659.6611 Tm
0 Tr
0 0 0 1 k
0.003 Tc
0 Tw
(-1)Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 438.2992 657.021 Tm
0 Tr
0 0 0 1 k
0.003 Tc
0.122 Tw
(\237st\237nde epidural yoldan)Tj
-12.64882 -1.3 TD
0 Tc
0.07 Tw
[(droperidol uygulad\335klar\335 3)-320(hastada akut distonik reaksi-)]TJ
0.0204 Tc
(yon)'
1.9362 0 Td
0.02 Tc
0.104 Tw
(g\232zlemi\337 ve olu\337an bu yan etkileri kulland\335klar\335)Tj
-1.9362 -1.3 TD
0 Tc
0 Tw
(y\237ksek doz droperidole ba\333lam\335\337lard\335r )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 468.4175 620.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((29))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 481.7417 618.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-16.99307 -2.6 TD
0.089 Tw
(Metoklopramidin neden oldu\333u ekstrapiramidal yan et-)Tj
0 -1.3 TD
0.024 Tw
(kilerin olu\337ma s\335kl\335\333\335 ise 1/500 olarak hesaplanm\335\337t\335r ve)Tj
T*
0.064 Tw
(ailesel bir \232zellik g\232sterdi\333ini iddia eden yay\335nlar mev-)Tj
T*
0 Tw
(cuttur )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 337.6338 555.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((30))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 350.958 553.0211 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-3.9147 -2.6 TD
0.019 Tc
0.106 Tw
(Akut distonik reaksiyonlar\335n butirifenonlarla nadiren)Tj
0 -1.3 TD
0 Tc
0.087 Tw
[(olu\337an n\232roleptik habis)-337(sendrom ile ay\335r\335c\335 tan\335s\335 \232nem)]TJ
0 -1.30001 TD
0.001 Tc
0.124 Tw
(ta\337\335r. N\232roleptik )Tj
7.06751 0.00001 TD
[(habis)-375(sendrom klinik olarak habis)-375(hi)-1(-)]TJ
-7.06751 -1.30001 TD
0 Tc
0.125 Tw
[(pertermiye benzemekle birlikte,)-375(olu\337ma mekanizmalar\335)]TJ
0 -1.3 TD
0 Tw
[(farkl\335d\335r. N\232roleptik habis)-251(sendromda ate\337, kas rijiditesi,)]TJ
T*
0.102 Tw
(akinezi, bilin\215 bulan\335kl\335\333\335, dispne, titreme ve otonomik)Tj
T*
0.003 Tc
0.122 Tw
(instabilite ile birlikte ta\337ikardi, kardiyak aritmiler, kan)Tj
T*
0 Tc
0 Tw
(bas\335nc\335 de\333i\337iklikleri, l\232kositoz, serumda hepatik transa)Tj
22.24439 0 TD
(-)Tj
-22.24439 -1.3 TD
0.02 Tw
(minaz ve kas kreatin fosfokinaz d\237zeyi art\335\337\335 mevcuttur.)Tj
T*
0.021 Tw
(Maln\237trisyon, dehidratasyon, fiziksel egzersiz olu\337umu-)Tj
T*
0.004 Tc
0.121 Tw
(nu tetikleyebilecek risk fakt\232rleri olarak belirtilmekte-)Tj
T*
0.003 Tc
0.122 Tw
[(dir. Fatal seyredebilir, mortalite oran\335 yakla\337\335k %)-375(20\325-)]TJ
T*
0 Tc
0.083 Tw
(dir. Mekanik so\333utma, n\232rolepti\333in kesilmesi, kas gev-)Tj
T*
0.007 Tc
0.118 Tw
(\337eticiler, dantrolen, diazem ve bromokriptin \(2-20 mg)Tj
T*
0 Tc
0.12 Tw
[(iv.)-370(4x1\) gibi dopaminerjik agonistler sa\333alt\335mda kulla)-1(-)]TJ
T*
0 Tw
(n\335labilir )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 345.9687 334.6611 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
((6,7,11))Tj
ET
Q
q
BT
/F3 1 Tf
10 0 0 10 371.2929 332.021 Tm
0 Tr
0 0 0 1 k
0 Tc
(.)Tj
-5.94819 -2.6 TD
0.01 Tc
0.114 Tw
[(Bu olgulardan yola \215\335karak,)-376(antiemetik olarak \232nemli)]TJ
0 -1.3 TD
0 Tc
0.094 Tw
(bir yere sahip olan ve s\335k kullan\335lan metoklopramid ve)Tj
T*
0.022 Tc
0.103 Tw
(droperidol\237n ender g\232zlenen, hasta i\215in \215ok rahats\335z)Tj
T*
0 Tc
0.077 Tw
[(edici olan,)-327(ancak uygun tedavi ile h\335zla d\237zelen ekstra-)]TJ
T*
0.07 Tw
(piramidal yan etkilere sahip oldu\333unu vurgulamak iste-)Tj
T*
0 Tw
(riz.)Tj
ET
Q
q
BT
/F0 1 Tf
10 0 0 10 311.811 215.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(KAYNAKLAR)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 195.021 Tm
0 Tr
0 0 0 1 k
0.007 Tc
0.118 Tw
(1. Kapur PA:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 363.4026 195.021 Tm
0 Tr
0 0 0 1 k
0.007 Tc
0.118 Tw
(The big "little problem". Anesth Analg 73:243-245,)Tj
-6.44895 -1.125 TD
0 Tc
0 Tw
(1991.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 177.021 Tm
0 Tr
0 0 0 1 k
0.006 Tc
0.119 Tw
(2. Watcha MF, White PF:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 408.1814 177.021 Tm
0 Tr
0 0 0 1 k
0.006 Tc
0.119 Tw
(Postoperative nausea and vomiting. Its)Tj
-12.0463 -1.125 TD
0.03 Tc
0.094 Tw
(etiology, treatment, and prevention. Anesthesiology 77:162-184,)Tj
T*
0 Tc
0 Tw
(1992.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 150.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.02 Tw
(3. Camu F, Lauwers MH, Verbessem D: )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 452.0213 150.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.02 Tw
(Incidence and aetiology of)Tj
-17.52629 -1.125 TD
0.046 Tw
(postoperative nausea and vomiting. Eur J Anaesthesiol 9(suppl 6):25-)Tj
T*
0 Tw
(31, 1992.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 123.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.078 Tw
(4. Andrews PLR:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 375.0079 123.021 Tm
0 Tr
0 0 0 1 k
0 Tc
0.078 Tw
(Physiology of nausea and vomiting. Br J Anaesth)Tj
ET
0 0 0 0 k
56.693 789.197 141.732 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 57.6929 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(V. Hanc\335 ve ark., Akut distonik reaksiyon)Tj
ET
0 0 0 0 k
526.249 92.168 12.334 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 527.2488 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(55)Tj
ET
Q
endstream
endobj
6 0 obj
<<
/Length 9691
>>
stream
/GS0 gs
q
0 0.89 595 841 re
W n
1 g
0 841.89 0 0 re
f
Q
/GS1 gs
q
0 0 0 0 k
56.693 432.055 481.89 324.796 re
f
Q
q
BT
/F3 1 Tf
8 0 0 8 57.6929 749.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(69(suppl 1):2-19, 1992.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 740.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.118 Tw
(5. Lerman J:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 106.7398 740.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.118 Tw
(Surgical and patient factors involved in postoperative)Tj
-6.13086 -1.125 TD
0 Tw
(nausea and vomiting. Br J Anaesth 69(suppl 1):24-32, 1992.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 722.587 Tm
0 Tr
0 0 0 1 k
0.006 Tc
0.119 Tw
(6. Miller R:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 102.9128 722.587 Tm
0 Tr
0 0 0 1 k
0.006 Tc
0.119 Tw
(Droperidol. In Anesthesia, 5th edition, eds. Cucchiara)Tj
-5.65249 -1.125 TD
0 Tc
0.006 Tw
(RF, Miller DE, Reves GJ, Roizen MF, Savarese JJ: Churchill Livings-)Tj
T*
0 Tw
(tone, Inc, 257-259, 2000.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 695.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.044 Tw
(7. Kayaalp SO:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 112.9749 695.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.044 Tw
(N\232roleptik \334la\215lar. In T\335bbi Farmakoloji ed. Kayaalp)Tj
-6.91025 -1.125 TD
0 Tw
(SO. Feryal matbaas\335, Ankara, 1862-1874, 1995.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 677.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.068 Tw
(8. Tang J, Watcha MF, White PF: )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 179.6884 677.587 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(A)Tj
1.0396 0 Td
0 Tc
0.068 Tw
(comparison of costs and effi-)Tj
-16.28904 -1.125 TD
0.008 Tw
(cacy of ondansetron and droperidol as prophylactic antiemetic therapy)Tj
T*
0.041 Tw
(for elective outpatient gynecologic procedures. Anesth Analg 83:304-)Tj
T*
0 Tw
(313, 1996.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 641.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.009 Tw
(9. Fortney JT, Gan TJ, Graczsk S ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 201.8814 641.587 Tm
0 Tr
0 0 0 1 k
-0.0001 Tc
(A)Tj
0.98092 0 Td
0 Tc
0.009 Tw
(comparison of the effi-)Tj
-19.00448 -1.125 TD
0.043 Tw
(cacy, safety, and patient satisfaction of ondansetron versus droperidol)Tj
T*
0.009 Tc
0.116 Tw
(as antiemetics for elective outpatient surgical procedures. S3A-409)Tj
T*
0 Tc
0 Tw
(and S3A-410 Study Groups . Anesth Analg 86:731-738, 1998.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 605.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.102 Tw
(10. Henzi I, Sonderegger J, Tramer MR:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 204.2512 605.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.102 Tw
(Efficacy, dose-response,)Tj
-18.31979 -1.125 TD
0.097 Tw
(and adverse effects of droperidol for prevention of postoperative na-)Tj
T*
0 Tw
(usea and vomiting. Can J Anaesth 47:537-551, 2000.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 578.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.084 Tw
(11. Anagnostou JM, Stoelting RK:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 180.3612 578.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.084 Tw
(Complications of Drug Used in)Tj
-15.33354 -1.125 TD
0.013 Tw
(Anesthesia. In Anesthesia & Perioperative Complications, second edi-)Tj
T*
0.01 Tc
0.114 Tw
(tion, eds. Benumorf J, Saidman L, Mosby \334nc, St Louis, Missouri,)Tj
T*
0 Tc
0 Tw
(161-191, 1999.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 542.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.051 Tw
(12. Bailey P, Norton R, Karan S:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 174.3152 542.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.051 Tw
(The FDA Droperidol Warning: \334s)Tj
-14.57779 -1.125 TD
0 Tw
(\334t Justified? Anesthesiology 97:288, 2002.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 524.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.115 Tw
(13. Drolet B, Zhang S, Deschenes D ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 214.7947 524.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.115 Tw
(Droperidol lengthens)Tj
-19.63772 -1.125 TD
0.064 Tw
(cardiac repolarization due to block of the rapid component of the de-)Tj
T*
0.051 Tc
0.074 Tw
(layed rectifier potassium current. J Cardiovasc Electrophysiol)Tj
T*
0 Tc
0 Tw
(10:1597-1604, 1999.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 488.587 Tm
0 Tr
0 0 0 1 k
0.03 Tc
0.095 Tw
(14. Palombaro JF, Klingelberger CE:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 199.9992 488.587 Tm
0 Tr
0 0 0 1 k
0.029 Tc
0.095 Tw
(Angioedema Associated)Tj
-17.78829 -1.125 TD
0.015 Tc
0.109 Tw
(With Droperidol Administration. American College of Emergency)Tj
T*
0 Tc
0 Tw
(Physicians 27:379-381, 1996.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 57.6929 461.587 Tm
0 Tr
0 0 0 1 k
0.021 Tc
0.104 Tw
(15. Passman R, Kadish A:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 156.9925 461.587 Tm
0 Tr
0 0 0 1 k
0.021 Tc
0.104 Tw
(Polymorphic ventricular tachycardia,)Tj
-12.41245 -1.125 TD
0.013 Tc
0.112 Tw
(long Q-T syndrome, and torsades de pointes. Med Clin North Am)Tj
T*
0 Tc
0 Tw
(85:321-341, 2001.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 749.587 Tm
0 Tr
0 0 0 1 k
0.029 Tc
0.095 Tw
(16. Zofran [package insert]:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 419.2472 749.587 Tm
0 Tr
0 0 0 1 k
0.029 Tc
0.095 Tw
(Research Triangle Park : GlaxoS-)Tj
-13.42952 -1.125 TD
0 Tc
0 Tw
(mithKline; 2000. )Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 731.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.047 Tw
(17. Kayaalp SO:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 371.1633 731.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.047 Tw
(Emetik ve Antiemetik \334la\215lar. In T\335bbi Farmakoloji)Tj
-7.41903 -1.125 TD
0 Tw
(ed. Kayaalp SO. Feryal matbaas\335, Ankara, 3210-3230, 1995.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 713.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.02 Tw
(18. Henzi I, Walder B, Tramer MR: )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 437.8044 713.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.02 Tw
(Metoclopramide in the preven-)Tj
-15.74917 -1.125 TD
0.125 Tw
(tion of postoperative nausea and vomiting: a quantitative systematic)Tj
T*
0.021 Tc
0.104 Tw
(review of randomized, placebo - controlled studies. Br J Anaesth)Tj
T*
0 Tc
0 Tw
(83(5):761-771, 1999.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 677.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.051 Tw
(19. Nielsen AS, Mors NP, Afdeling B ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 468.348 677.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.051 Tw
(Atypical acute dysto-)Tj
-19.56712 -1.125 TD
0 Tw
(nia. Ugeskr Laeger 160(51):7441-7442, 1998.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 659.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.113 Tw
(20. Etzel JV:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 360.2789 659.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.113 Tw
(Diphenhydramine-induced acute dystonia. Pharmacot-)Tj
-6.05848 -1.125 TD
0 Tw
(herapy 14(4):492-496, 1994.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 641.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.015 Tw
(21. Hooker EA, Danzl DF:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 404.604 641.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.015 Tw
(Acute dystonic reaction due to diazepam.)Tj
-11.59912 -1.125 TD
-0.0001 Tc
(J)Tj
0.63889 0 Td
0 Tc
0 Tw
(Emerg Med 6:491-493, 1988.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 623.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.074 Tw
(22. Kapur V, Barber KR, Peddireddy R: )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 456.8037 623.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.074 Tw
(Ranitidine-induced acute)Tj
-18.12409 -1.125 TD
0 Tw
(dystonia. Am J Emerg Med 17(3):258-260, 1999.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 605.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.065 Tw
(23. Wilson LB, Woodward AM, Ferrara JJ:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 467.4006 605.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.065 Tw
(An acute dystonic re-)Tj
-19.4487 -1.125 TD
0.084 Tw
(action with long-term use of ranitidine in an intensive care unit pati-)Tj
T*
0 Tw
(ent. J La State Med Soc 149(1):36-38, 1997.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 578.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.016 Tw
(24. Palop V, Jimenez MJ, Catalan C ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 464.9132 578.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.016 Tw
(Acute dystonia associ-)Tj
-19.13777 -1.125 TD
0.075 Tc
0.099 Tw
(ated with fluvoxamine-metoclopramide. Ann Pharmacother)Tj
T*
0 Tc
0 Tw
(33(3):382, 1999.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 551.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.031 Tw
(25. Hagen EM, Farbu E, Bindoff:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 429.5189 551.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.031 Tw
(Acute dystonia caused by Metoc-)Tj
-14.71348 -1.125 TD
0.125 Tw
(lopramide (Afipran) therapy. Tidsskr Nor Laegeforen 121(18):2162-)Tj
T*
0 Tw
(2163, 2001.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 524.587 Tm
0 Tr
0 0 0 1 k
0.015 Tc
0.11 Tw
(26. Pina MA, Ara JR, Remirez A, ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 467.4405 524.587 Tm
0 Tr
0 0 0 1 k
0.015 Tc
0.11 Tw
(Verapamil and acute)Tj
-19.45368 -1.125 TD
0 Tc
0 Tw
(dystonia. J Clin Pharm Ther 23:79-80, 1998.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 506.587 Tm
0 Tr
0 0 0 1 k
0.013 Tc
0.112 Tw
(27. Granisetron Hydrochloride:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 428.4646 506.587 Tm
0 Tr
0 0 0 1 k
0.013 Tc
0.112 Tw
((003157) Mosby's Drug Consult)Tj
-14.5817 -1.125 TD
0 Tc
0 Tw
(Copyright \251 Mosby, Inc. 2002.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 488.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.073 Tw
(28. Yotsui H, Matsunaga M, Katori K, ve ark: )Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 476.3699 488.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.073 Tw
(Extrapyramidal re-)Tj
-20.56986 -1.125 TD
0 Tw
(actions after epidural droperidol. Masui 49:1152-1154, 2000.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 470.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.005 Tw
(29. Shimada J, Akama Y, Tase C, ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 455.0485 470.587 Tm
0 Tr
0 0 0 1 k
0 Tc
0.005 Tw
(Problems of epidural dro-)Tj
-17.90468 -1.125 TD
0 Tw
(peridol administration. Masui 43:1248-1250, 1994.)Tj
ET
Q
q
BT
/F0 1 Tf
8 0 0 8 311.811 452.587 Tm
0 Tr
0 0 0 1 k
0.027 Tc
0.098 Tw
(30. Guala A, Mittino D, Ghini T, ve ark:)Tj
ET
Q
q
BT
/F3 1 Tf
8 0 0 8 467.1216 452.587 Tm
0 Tr
0 0 0 1 k
0.027 Tc
0.098 Tw
(Are metoclopramide)Tj
-19.41382 -1.125 TD
0 Tc
0 Tw
(dystonias familial? Pediatr Med Chir 14:617-618, 1992.)Tj
ET
0 0 0 0 k
410.956 789.197 127.627 10.173 re
f
Q
q
BT
/F1 1 Tf
8 0 0 8 411.9562 792.4114 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(G\232ztepe T\335p Dergisi 20(1):53-56, 2006)Tj
ET
0 0 0 0 k
56.693 92.168 12.334 12.714 re
f
Q
q
BT
/F0 1 Tf
10 0 0 10 57.6929 96.4236 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(56)Tj
ET
Q
endstream
endobj
7 0 obj
<<
/Nums[0<>]
>>
endobj
8 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 40/parenleft/parenright/asterisk 44/comma/hyphen/period 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W/X/Y/Z/bracketleft 93/bracketright 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v/w 121/y/z 222/fi]
>>
endobj
9 0 obj
<<
/Subtype/Type1C
/Length 8096
/Length1 8096
>>
stream
IJWDXE+TimesTurkB ?ø øøøøRû”ú„úY
‹‹
‹‹ ¹ µ D‘ š %DNMacromedia Fontographer 4.1.5 4/1/99Generated by Fontographer 4.1.5TimesTurkB D 4 6 . " 3 : D V U F E Z T P O J S B 0 - ( M H 5 * m L 7 ) / $
9 , Q 1 8 I '
N X C % + [ W # ; &